Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

@article{Stack1997RandomisedCT,
  title={Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.},
  author={William A Stack and Steven D. Mann and Anthony J. Roy and Peter Heath and Mark Sopwith and Jane Freeman and Gregory Holmes and Richard Long and Alastair Forbes and M. Kamm},
  journal={Lancet},
  year={1997},
  volume={349 9051},
  pages={521-4}
}
BACKGROUND Tumour necrosis factor-alpha (TNF alpha) is thought to have a central role in the pathogenesis of Crohn's disease. We tested the hypothesis that CDP571, a genetically engineered human antibody to TNF alpha, is effective in modifying disease activity in patients with moderately active Crohn's disease. METHODS In this double-blind, placebo-controlled study, 31 patients were randomly assigned to CDP571 (n = 21) or placebo (n = 10). The primary endpoint was change in Crohn's disease… CONTINUE READING